MARKET
IPO

DRMT

Dermavant Scienc
DRMT
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
16.79~19.59
-
16.79~19.59
294.47M~343.55M
Pharmaceuticals
2019-05-24
Public Filing
View Prospectus
Pending
Offering
Price Range: 12.00~14.00
Shares to be Issued: 7700.00K
Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 24.54M
Listed
No Data
About DRMT
Dermavant Sciences Ltd is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics in medical dermatology. The Company is developing its lead product candidate tapinarof as a differentiated therapeutic aryl hydrocarbon receptor modulating agent, or TAMA, topical cream for the treatment of psoriasis and atopic dermatitis. The Company’s products include tapinarof (DMVT-505), cerdulatinib (DMVT-502), oxybutynin (DMVT-504), DMVT-503 and lotamilast Gel (DMVT-501). The Company has commenced two pivotal Phase II clinical trials of tapinarof for the treatment of psoriasis.

Webull offers Dermavant Scienc stock information, including NASDAQ: DRMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRMT stock methods without spending real money on the virtual paper trading platform.